此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

对消融的恶性肝转移组织的检查作为结果的预测指标

2026年11月2日 更新者:Memorial Sloan Kettering Cancer Center

The purpose of this study is to see if the investigators can do some tests on tissue from the area of the ablation. The investigators want to know if a test can help predict whether the ablation worked.

The treated tumor is normally evaluated with CT. The CT shows signs of treated tumor(s) in the area treated by ablation. However, cancer cells may begin to grow in or near the treated area. The CT scan cannot tell us if the cells are new cancer cells or if they are healthy liver cells that just look different because of the ablation. The test the investigators will study should be able to tell us the difference.

研究概览

地位

主动,不招人

条件

研究类型

介入性

注册 (实际的)

150

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • New York
      • New York、New York、美国、10065
        • Memorial Sloan Kettering Cancer Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Patients with diagnosed with secondary hepatic malignancy;
  • Patients with confined liver disease or stable limited extrahepatic disease;
  • Lesions of 5cm or less in maximum diameter;
  • Patients who are not surgical candidates or refuse to undergo surgery and choose any percutaneous ablation as an alternative treatment option.
  • INR<1.5 *for patients on Coumadin general clinical guidelines for IR ablation will be followed.
  • Platelet count > or = to 50,000

Exclusion Criteria:

  • Patients < 18

  • Less than 5 mm distance of the tumor margin from a major vessel >7mm in diameter)**

  • Less than 5 mm distance to a structure (GI or biliary tract), that cannot be protected from**

  • the ablation injury with technical modifications such as hydro or air dissection.

  • INR > 1.5 that cannot be corrected with fresh frozen Plasma*

  • Platelet count of <50,000 that cannot be corrected with transfusion.

  • Patient with more than 3 tumors treated with any percutaneous ablation

  • Patients with more than 5 sites of extrahepatic disease (including nodes and pulmonary nodules)

    • for patients on Coumadin general clinical guidelines for IR ablation will be followed **This will not be considered an exclusion criteria when IRE or Microwave is used.

      • This will not be considered exclusion when IRE is used

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:诊断
  • 分配:不适用
  • 介入模型:单组作业

武器和干预

参与者组/臂
干预/治疗
实验性的:CT guided percutaneous ablation

The selected patients will undergo CT guided percutaneous ablation. The use of multi-tined electrode is encouraged, unless tumor location requires the use of an internally cooled needle electrode to eliminate injury to an adjacent vital structure or the operator prefers to use an internally cooled electrode for a specific reason.

Depending on tumor size and location, we will direct a core biopsy needle in the ablated tumor using post-ablation dynamic Liver CT guidance, preferably including liver triphasic examination. The obtained tissue will be detached, collected and submitted to our molecular cytology laboratory. All specimens will be submitted fresh to our molecular cytology laboratory for immediate analysis in order to classify them as viable tumor (V) or apoptotic cells/coagulation necrosis (CN). CT will be performed within 24 hours of the ablation to demonstrate the ablation defect, representing the area of coagulation necrosis. This CT will be used for targeting the ablated tumor for biopsy. All patients will undergo CT again, approximately within 4-8 weeks (+/- 2 weeks) of percutaneous ablation to evaluate for CN in the target tumor or any sign of residual tissue enhancement, representing incomplete treatment.

其他名称:
  • 将继续以大约 2-4 个月的间隔(+/- 2 周)使用 CT 进行随访,以评估接下来 3 年的局部肿瘤进展 (LTP)。

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Tumor response
大体时间:3 years

will be measured according to EASL and RECIST. In the case of differences between these criteria, the EASL criteria will be used for clinical judgment and decisions.Tumor response will be determined at the discretion of the Principal Investigator in the case of overlapping ablation zones or lesions seen only in PET.

3 years

次要结果测量

结果测量
措施说明
大体时间
Duration of treatment response
大体时间:3 years

will be measured as the time from the date of first objective response until the first measurement of progression as determined by the central readers using the EASL criteria. Dynamic Liver CT scans, preferably including the liver triphasic examination will be conducted at each follow-up visit until progression.

3 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Constantinos Sofocleous, MD、Memorial Sloan Kettering Cancer Center

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2009年10月27日

初级完成 (估计的)

2027年10月1日

研究完成 (估计的)

2027年10月1日

研究注册日期

首次提交

2011年12月13日

首先提交符合 QC 标准的

2011年12月14日

首次发布 (估计的)

2011年12月19日

研究记录更新

最后更新发布 (实际的)

2026年11月3日

上次提交的符合 QC 标准的更新

2026年11月2日

最后验证

2026年11月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅